Runanine is used in the development of antiviral medications, particularly targeting RNA viruses. It acts as a nucleoside analog, interfering with viral replication by inhibiting key enzymes such as RNA polymerase. This compound has shown promise in preclinical studies for treating respiratory infections due to its ability to reduce viral load with minimal cytotoxicity. Additionally, Runanine is being explored for its potential in combination therapies to enhance antiviral efficacy and reduce the risk of drug resistance. Its structural flexibility allows for chemical modifications to improve bioavailability and target specificity.